MAP

MICROBA FPO [MAP]
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Healthcare · ASX Small Cap
$0.0420 -4.6%

Updated 22 Jul 2026 · Signals refresh every scan

⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Get alerts when MAP triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track MAP — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Bollinger Bands are tightening — volatility is coiling up for a potential breakout
  • Beating the Small Ords index — relative strength of 1.13, so it's outpacing the pack
  • Low cash runway (3 quarters) - dilution risk
  • 4C filed 2026-07-15
  • Low P/S ratio (2.1x)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (13% of range)
  • Small-cap ($20-100M)
  • CANSLIM S: Tight float (30%)
  • CANSLIM I: Institutional ownership (24%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 52% over the past year
  • Low-priced stock risk ($0.045)
  • RBA hiking (-3pts)

Risk Signals

  • Stochastic turning bearish from a high level — caution
  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-10%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-133%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-2.05%/day)
Ask Scout AI about MAP
"What's driving MAP today?" "How does MAP compare to peers?" "Key risks for MAP?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Microba signs multi-year SYNLAB agreement
NONE Change in substantial holding
LOW Q4 FY26 Quarterly Investor Presentation & Webinar
LOW Q4 FY26 Quarterly Activities Report & Appendix 4C
LOW Details of Q4 FY26 Quarterly Report, Appendix 4C & Webinar

Recent ASX Announcements

2026-07-19 Microba signs multi-year SYNLAB agreement
2026-07-15 Q4 FY26 Quarterly Investor Presentation & Webinar PRICE SENSITIVE
2026-07-15 Q4 FY26 Quarterly Activities Report & Appendix 4C PRICE SENSITIVE
2026-07-14 Change in substantial holding
2026-07-14 Details of Q4 FY26 Quarterly Report, Appendix 4C & Webinar

Key Metrics

$31.5M
Market Cap
1.1M
Avg Volume
0.9x
Vol Ratio
$0.04 — $0.10
52-Week Range
N/A
Short Interest
3 qtrs
Cash Runway
-60.0%
ROE
-132.5%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 30%
LLeader vs LaggardlaggardRS: -19
IInstitutional SponsorshippassInst: 24%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:MAP vs IDTMAP vs ADRMAP vs LDX
Scout Pro — Deeper Analysis for MAP
Try Pro free for 30 days
Share this analysis

Track MAP and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required